Inflammatory biomarkers of low back pain and disc degeneration: a review.
Inflammatory biomarkers of low back pain and disc degeneration: a review.
复制标题
DOI：
10.1111/nyas.13551
复制
发表时间：
2017-12
影响因子：
5.2
通讯作者：
Chahine NO
中科院分区：
文献类型：
--
作者：
Khan AN;Jacobsen HE;Khan J;Filippi CG;Levine M;Lehman RA Jr;Riew KD;Lenke LG;Chahine NO
生物标志物是可用于指示健康或疾病的生物特征。本文综述了人类下腰痛（LBP）生物标志物的研究。LBP是残疾的主要原因，由各种脊柱相关疾病引起，包括椎间盘退变、椎间盘突出、椎管狭窄和小关节炎。这些研究的重点是炎症介质，因为炎症有助于椎间盘退变的发病机制和相关的疼痛机制。越来越多的研究表明，炎症介质的存在可以在血液中进行全身测量。这些生物标志物可以作为指导患者护理的新工具。目前，患者对治疗的反应是不可预测的，具有显著的复发率，并且，虽然手术治疗可以提供解剖矫正和疼痛缓解，但它们是侵入性的且昂贵的。该综述涵盖了对具有特定诊断和未定义LBP起源的人群进行的研究。由于LBP的自然病程是进行性的，因此研究的时间性质按病理学/疾病的持续时间分类。生物标志物的变化与治疗的相关研究也进行了审查。最终，LBP和脊柱退变的诊断生物标志物有可能引领一个个性化脊柱医学时代，用于治疗LBP的个性化治疗。
Biomarkers are biological characteristics that can be used to indicate health or disease. This paper reviews studies on biomarkers of low back pain (LBP) in human subjects. LBP is the leading cause of disability, caused by various spine-related disorders, including intervertebral disc degeneration, disc herniation, spinal stenosis, and facet arthritis. The focus of these studies is inflammatory mediators, because inflammation contributes to the pathogenesis of disc degeneration and associated pain mechanisms. Increasingly, studies suggest that the presence of inflammatory mediators can be measured systemically in the blood. These biomarkers may serve as novel tools for directing patient care. Currently, patient response to treatment is unpredictable with a significant rate of recurrence, and, while surgical treatments may provide anatomical correction and pain relief, they are invasive and costly. The review covers studies performed on populations with specific diagnoses and undefined origins of LBP. Since the natural history of LBP is progressive, the temporal nature of studies is categorized by duration of symptomology/disease. Related studies on changes in biomarkers with treatment are also reviewed. Ultimately, diagnostic biomarkers of LBP and spinal degeneration have the potential to shepherd an era of individualized spine medicine for personalized therapeutics in the treatment of LBP.
登录
查看更多内容
影响因子：
3
作者：
DEYO, RA;TSUIWU, YJ
通讯作者：
TSUIWU, YJ
影响因子：
7.3
作者：
CUNHA, FQ;POOLE, S;FERREIRA, SH
通讯作者：
FERREIRA, SH
DOI：
10.1016/j.berh.2010.10.002
发表时间：
2010-12-01
影响因子：
5.2
作者：
Hoy, D.;Brooks, P.;Buchbinder, R.
通讯作者：
Buchbinder, R.
影响因子：
2.8
作者：
Auerbach, Joshua D.;Johannessen, Wade;Elliott, Dawn M.
通讯作者：
Elliott, Dawn M.
影响因子：
3.1
作者：
Grad, S.;Bow, C.;Samartzis, D.
通讯作者：
Samartzis, D.